RxDoctor Payments Data

Jonathan Halperin, MD

Cardiovascular Disease · New York, NYNPI 1508805227

Payments from drug & device makers

$45,845in general payments, 2019–2025

Across 31 payments — averaging $1478.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim International GmbH$20K
  • Bayer$15K
  • Janssen Research & Development, LLC$4K
  • Daiichi Sankyo Inc.$3K
  • Boehringer Ingelheim India Pvt. Ltd.$2K
  • Boehringer Ingelheim$1K
  • plus $364 from 2 others

What the payments were for

  • Consulting fees$27,28060%
  • Speaking & faculty fees$13,67930%
  • Travel & lodging$4,2959%
  • Food & beverage$5911%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boehringer Ingelheim International GmbH16$20,214
Bayer3$15,165
Janssen Research & Development, LLC1$3,500
Daiichi Sankyo Inc.3$3,000
Boehringer Ingelheim India Pvt. Ltd.1$2,360
Boehringer Ingelheim3$1,242
Johnson & Johnson2$265
Bioventus LLC2$98

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$45,845 in reported general payments places this provider in the 90th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$107,994
Medicare patients
578
Services billed
1,413

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban189$243,656
XareltoRivaroxaban89$102,111
JardianceEmpagliflozin38$56,598
EntrestoSacubitril/Valsartan29$44,029
MultaqDronedarone Hcl27$37,100
LivaloPitavastatin Calcium12$7,928
Dabigatran EtexilateDabigatran Etexilate Mesylate19$7,511
PradaxaDabigatran Etexilate Mesylate17$7,019
Atorvastatin Calcium308$3,677
Metoprolol Succinate182$3,160
Nebivolol Hcl31$2,967
Rosuvastatin Calcium127$1,938
Candesartan Cilexetil22$1,759
Losartan Potassium131$1,503
Amlodipine Besylate177$1,482

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$265$102,11189 claims
Boehringer IngelheimJardiance, Pradaxa$1,242$63,61755 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →